Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3133642 | 0.83 | — | — | |
| SCHEMBL28619339 | 0.79 | DYRK1A (0.32) | DYRK1AADORA2AADORA1 | |
| SCHEMBL28034702 | 0.77 | ALDH1A1 (0.51) | — | |
| SCHEMBL19692379 | 0.74 | — | — | |
| SCHEMBL5985571 | 0.74 | — | — | |
| SCHEMBL7876670 | 0.74 | — | — | |
| SCHEMBL8944768 | 0.74 | — | — | |
| N4-Hydroxycytosine SCHEMBL48396 | 0.74 | — | — | |
| SCHEMBL11894063 | 0.74 | — | — | |
| SCHEMBL27952254 | 0.74 | NCF1 (0.39) | DYRK1AADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE46171-E1 | Functional biopolymer modification reagents and uses thereof | SOLULINK, INCORPORATED (US) | 2016-10-04 | — | — | US | disclosed |
| US-7732628-B2 | Such as 4-[8-(2-cyanoethyl-N,N-diisopropylphosphoramidyloxy)-2-aza-1-oxooct-1-yl]benzaldehyde, 4-[8-(2-cyanoethyl-N,N-diisopropylphosphoramidyloxy)-2-aza-1-oxooct-1-yl]acetophenone; for incorporation into oligonucleotides during immobilization and conjugation of biopolymers in solid phase synthesis | SOLULINK INCORPORATED (US) | 2010-06-08 | — | — | US | disclosed |
| US-7102024-B1 | Functional biopolymer modification reagents and uses thereof | AUDAX PRIVATE DEBT LLC, AS AGENT | 2006-09-05 | — | — | US | disclosed |
| US-20050203289-A1 | Functional biopolymer modification reagents and uses thereof | AUDAX PRIVATE DEBT LLC, AS AGENT | 2005-09-15 | — | — | US | disclosed |
| WO-2002010431-A2 | FUNCTIONAL BIOPOLYMER MODIFICATION REAGENTS AND USES THEREOF | SCHWARTZ DAVID A (US) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203289-A1 | Functional biopolymer modification reagents and uses thereof | OGG1, OGA, HMOX2 | DYRK1A 2914/4885ADORA2A 1916/4885ADORA1 2997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.